Clinical trial Recruiting at 1 site Observational Ages 18 and up

Smartphone-based screening for aortic valve stenosis

Official title: Smartphone Based Digital Screening for Aortic Valve Stenosis

Run by Medical University Innsbruck · NCT07284550 · Data updated 2026-11-12

A smartphone-based screening approach is being tested to see if it can help identify aortic valve stenosis in adults, using signals captured by the device.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment500 (estimated)
SponsorMedical University Innsbruck
Academic / other
Locations1 site (Innsbruck)
StatusRecruiting
StartedJanuary 12, 2026
Main results expectedNovember 2028
Study endsNovember 2029
Registry record updatedMay 28, 2026
Trial IDNCT07284550 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years or older who have either moderate to severe aortic valve stenosis or no significant valvular disease, with recent echocardiography within 90 days and who can provide informed consent.

Probably not a fit

Patients with other significant valvular heart diseases, prior valvular prostheses or certain cardiac conditions, or those unable to use smartphone-based tools may not benefit from this screening approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study explores whether a smartphone-based signal acquisition method can help screen for aortic valve stenosis. Participants include adults with moderate to severe disease and those without significant valvular disease, using routine echocardiography as a reference. The study focuses on leveraging artificial intelligence and accessible technology to enable broad, low-cost screening outside traditional imaging settings. Data will be collected from smartphone signals and analyzed to see if they can indicate the presence of clinically relevant valve narrowing. No interventional procedures are involved; the aim is to assess feasibility and potential diagnostic value in real-world clinical practice.

Why it matters

Potential benefit: If successful, the approach could provide a simple and widely accessible screening option to help detect aortic valve stenosis earlier.

How similar studies have gone: Previous efforts with smartphone-based screening and AI tools show promise but results are variable; this study contributes to emerging evidence in a real-world setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
The following inclusion and exclusion criteria will be used for training, validation and test sets:

Inclusion criteria for group I (moderate to severe AS):

* Moderate to severe AS defined as AVA ≤ 1.5cm² in echocardiographic assessment
* No other significant VHD, valvular prosthesis, pacemaker or congenital heart defect
* Documented echocardiography as part of routine clinical practice no older than 90 days
* Patient age ≥ 18 years
* Provided written informed consent

Inclusion criteria for group II:

* No significant VHD, valvular prosthesis, pacemaker or congenital heart defect
* Documented echocardiography as part of routine clinical practice no older than 90 days
* Patient age ≥ 18 years
* Provided written informed consent

Exclusion criteria (applicable for all groups):

• Informed consent form not signed.

Where it's running

  • Department of Internal Medicine III
    Innsbruck, Austria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.